India, June 26 -- ReShape Lifesciences Inc. (RSLS), Thursday announced its decision to reduce its workforce, which is expected to generate annualized savings of over $750,000 or 23.4 percent of annual payroll expenses.
The decision, expected to boost operational efficiency of the company, comes after conducting a thorough review of its operating structure.
Concurrently, the company also shared an update regarding its merger agreement with Vyome Therapeutics and the asset sale to Biorad Medisys. These strategic transactions were unanimously endorsed by the Board of Directors.
In the pre-market hours, RSLS is trading at $2.61, up 6.48 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital ...